secwatch.observer — SEC 8-K summary
======================================

Issuer:     Envoy Medical, Inc. (COCH)
CIK:        0001840877
Form:       8-K
Filed at:   2026-05-11T23:59:59+00:00
Accession:  0001213900-26-054185
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Envoy Medical completes pivotal trial enrollment for fully implanted cochlear implant; raises $30M
--------------------------------------------------------------------------------

- Completed enrollment of 56 patients in U.S. pivotal trial for Acclaim cochlear implant; first three patients reach 12-month endpoint.
- Closed upsized public offering for $30M gross proceeds (up to $78M with warrants); led by Nantahala Capital and Broadfin Holdings.
- Interim data from first 10 patients: CNC word recognition improved from 15.2% to 39.2%; no serious adverse events; 24-hour wear time.
- Q1 2026 revenue $39k; R&D expense $3.6M; cash $25.3M as of March 31, 2026.
- Appointed medical device veteran Chas McKhann to Board; expanded IP portfolio to 47 patents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840877/000121390026054185/0001213900-26-054185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840877/000121390026054185/ea0289965-8k_envoy.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-054185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer